Skip to main content
Insights
/ Webinars

Biopharma Dealmaking 2025

Wed, Jan 22, 2025
16:00 CET | 10:00 EST
Biopharma Dealmaking 2025

Reserve your seat

First name
Last name
Business email
Company name
Job title
Which sector best reflects your role?
By submitting this form, you agree to the storing and processing of your personal data by Inpart as detailed in the Privacy Statement.
After a year of modest M&A action and muted deal values, what happens next?

Leading firms are facing LOE pressures, there’s a new administration coming to Washington with promises to cut regulatory red tape, and there is plenty of cash in top pharma pockets to invest in new science. Venture capital is investing in AI-powered biotechs, confidence in money markets is increasing, and healthcare spending in emerging markets is on the rise. Are we on the verge of a bumper year for biopharma dealmaking?

Panelists

Chris Dokomajilar
Chris Dokomajilar
Founder and CEO — DealForma

Chris Dokomajilar, Founder and CEO of DealForma, joins Inpart this January for an exclusive webinar to review the year in dealmaking that was and explore what we can expect from the market in 2025. Drawing on DealForma’s market-leading datasets and fresh from all the deals made at the JP Morgan Healthcare Conference, Chris’s annual look at the dealmaking landscape is a can’t miss event.